PODD - Insulet Corporation
| Previous Close | 88.30 |
| Open | 89.00 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 800 |
| Day's Range | 87.86 - 89.79 |
| 52 Week Range | 54.55 - 102.89 |
| Volume | 399,017 |
| Avg. Volume | 735,412 |
| Market Cap | 5.276B |
| Beta | 1.45 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.30 |
| Earnings Date | Oct 31, 2018 - Nov 5, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 101.43 |
- Zacks•4 days ago
Zacks.com featured highlights include: Entercom, Insulet, ESCO and Tristate
Zacks.com featured highlights include: Entercom, Insulet, ESCO and Tristate
- Zacks•5 days ago
4 Top Stocks With the Power of Earnings Acceleration
Studies show that a majority of successful stocks see acceleration in earnings before a positive stock price movement.
- Business Wire•5 days ago
Insulet to Showcase Its Omnipod DASH™ Insulin Management System at the American Association of Diabetes Educators Annual Conference
Insulet Corporation , the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System , today announced it will showcase its recently FDA cleared Omnipod DASH™ Insulin Management System , during the American Association of Diabetes Educators meeting at the Baltimore Convention Center in Baltimore, Maryland on August 17-20, 2018.
- Thomson Reuters StreetEvents•6 days ago
Edited Transcript of PODD earnings conference call or presentation 2-Aug-18 8:30pm GMT
Q2 2018 Insulet Corp Earnings Call
Markit•10 days agoSee what the IHS Markit Score report has to say about Insulet Corp.
Insulet Corp NASDAQ/NGS:PODD
- Zacks•14 days ago
Insulet (PODD) Q2 Loss Narrower Than Expected, Revenues Lag
We are encouraged by the year-over-year improvement in Insulet's (PODD) results on solid uptake of Omnipod system in the United States in Q2.
Motley Fool•18 days agoInsulet Achieves Operating Profitability, but Pares Back 2018 Revenue Guidance
The tubeless insulin pump specialist's revenue growth slowed notably in the second quarter, but management said this is a short-term phenomenon related to the company's transition to a direct sales model in Europe.
- Zacks•18 days ago
Insulet (PODD) Reports Q2 Loss, Lags Revenue Estimates
Insulet (PODD) delivered earnings and revenue surprises of 76.92% and -6.52%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•18 days ago
Insulet: 2Q Earnings Snapshot
On a per-share basis, the Billerica, Massachusetts-based company said it had a loss of 3 cents. The results beat Wall Street expectations. The average estimate of 12 analysts surveyed by Zacks Investment ...
- Business Wire•18 days ago
Insulet Reports Second Quarter 2018 Revenue of $124.3 Million, Up 13% Year-Over-Year, and Gross Margin of 66%, Up 710 Basis Points
Full Year 2018 Expected Revenue Growth Revised to 18% to 21%
- ACCESSWIRE•18 days ago
Insulet Corporation to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 2, 2018 / Insulet Corporation (NASDAQ: PODD ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 4:30 PM Eastern Time. ...
- Benzinga•19 days ago
Q2 Earnings Outlook For Insulet
Don't be caught off-guard: Insulet (NASDAQ: PODD ) releases its next round of earnings Thursday. Want to skip the homework and get all the facts in one place? We thought so. Here is your everything-that-matters ...
- Zacks•22 days ago
Hill-Rom (HRC) Q3 Earnings Top Estimates, Margins Expand
Hill-Rom (HRC) registers a solid year-over-year revenue rise on strong domestic growth, driven by a robust performance at Patient Support Systems and Surgical Solutions.
- Zacks•24 days ago
Zimmer Biomet (ZBH) Q2 Earnings Top Estimates, Margins Drop
The improvement within Zimmer Biomet's (ZBH) global Knee and Hip sales performance and ongoing growth within the Asia Pacific region are encouraging.
- Zacks•25 days ago
GNC Holdings (GNC) Q2 Earnings Beat, Revenues Miss Mark
Though GNC Holdings' (GNC) domestic retail comps are slightly weaker than expected, the company performs strongly in e-commerce business and at International segment.
- Zacks•26 days ago
Align Technology (ALGN) Beats on Earnings and Revenues in Q2
Align Technology (ALGN) gains on solid contributions from Clear Aligner as well as Scanner and Service segments in Q2.
- Zacks•26 days ago
Chemed (CHE) Beats on Q2 Earnings & Revenues, View Raised
Chemed (CHE) rides on strong contributions from the Roto-Rooter and VITAS businesses in Q2.
- Zacks•27 days ago
Thermo Fisher (TMO) Beats on Q2 Earnings, Ups '18 EPS View
Thermo Fisher (TMO) is performing well on the back of a series of product launches along with major progress in precision medicine initiatives.
- Zacks•27 days ago
Boston Scientific (BSX) Beats on Q2 Earnings, Margins Down
Boston Scientific (BSX) registers steady growth across all business lines and geographies in Q2.
- Zacks•28 days ago
Quest Diagnostics (DGX) Q2 Earnings Meet, Guidance Narrowed
Quest Diagnostics (DGX) gains on successful execution of its two-point strategy of accelerating growth and driving operational excellence in Q2.
- Zacks•28 days ago
PetMed (PETS) Q1 Earnings Lag Estimates, Reorder Sales Solid
We are encouraged by growth in PetMed's (PETS) reorder and new order sales in Q1. Increased online sales buoy optimism.
Markit•29 days agoSee what the IHS Markit Score report has to say about Insulet Corp.
This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on July 19. Over the last one-month, outflows of investor capital in ETFs holding PODD totaled $1.24 billion.
- ACCESSWIRE•last month
Today’s Free Research Reports Coverage on Neovasc and Three More Healthcare Stocks
Under assessment this morning are these four equities: Myomo Inc. (NYSE AMER: MYO), Neovasc Inc. (NASDAQ: NVCN), Smith & Nephew PLC (NYSE: SNN), and Insulet Corp. (NASDAQ: PODD). All you have to do is sign up today for this free limited time offer by clicking the link below.
- Business Wire•last month
Insulet Extends Partnership with Glooko in Europe to Optimise Diabetes Data Management
Insulet Corporation (PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced that it has partnered with Glooko®, Inc. to connect Insulet’s Omnipod System user data with Glooko+diasend®, the most comprehensive diabetes data management system available, across Europe.
- Business Wire•last month
Insulet to Announce Second Quarter 2018 Financial Results on August 2, 2018
Insulet Corporation (PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced plans to release its financial results for the second quarter of 2018 on August 2, 2018 after the close of the financial markets. The link to the live call will be available on the Investor Relations section of the Company's website at http://investors.insulet.com, “Events and Presentations”, and will be archived for future replay. You may also access the live call by dialing (844) 831-3022 for domestic callers or (315) 625-6887 for international callers, passcode is 3342069.
